HomeInsightsStock Comparison

Natco Pharma Ltd vs Pentokey Organy India Ltd Stock Comparison

Natco Pharma Ltd vs Pentokey Organy India Ltd Stock Comparison

Last Updated on: Jun 15, 2025

Key Highlights

  • The Latest Trading Price of Natco Pharma Ltd is ₹ 912.55 as of 13 Jun 15:30.
  • The P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 yearsThe P/E Ratio of Pentokey Organy (India) Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 yearsThe Market Cap of Pentokey Organy (India) Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71% The revenue of Pentokey Organy (India) Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63% The ebitda of Pentokey Organy (India) Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% The net profit of Pentokey Organy (India) Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 yearsThe Dividend Payout of Pentokey Organy (India) Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

About Pentokey Organy (India) Ltd

  • Pentokey Organy (India) Ltd was incorporated on November 26, 1986.
  • The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
  • Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
  • Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
  • As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

Natco Pharma Ltd News Hub

News

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483. The...

Read more

14 Jun 2025 13:45

News

Natco Pharma's Mekaguda API unit completes USFDA inspection

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active P...

Read more

13 Jun 2025 16:27

News

Natco Pharma Ltd gains for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908...

Read more

11 Jun 2025 13:05

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

Pentokey Organy (India) Ltd News Hub

News

Pentokey Organy (India) schedules board meeting

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 24...

Read more

21 May 2025 20:05

News

Pentokey Organy (India) to discuss results

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 25...

Read more

22 Jan 2025 14:33

News

Pentokey Organy (India) AGM scheduled

Pentokey Organy (India) announced that the Annual General Meeting (AGM) of the company wil...

Read more

12 Aug 2024 15:56

News

Pentokey Organy (India) to declare Quarterly Result

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 10...

Read more

07 Aug 2024 12:36

News

Pentokey Organy (India) announces board meeting date

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 13...

Read more

08 May 2024 10:47

News

Pentokey Organy (India) to hold board meeting

Pentokey Organy (India) will hold a meeting of the Board of Directors of the Company on 27...

Read more

23 Jan 2024 12:39

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Pentokey Organy (India) Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Pentokey Organy (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Natco Pharma Ltd and Pentokey Organy (India) Ltd

Which company has a larger market capitalization, Natco Pharma Ltd or Pentokey Organy (India) Ltd?

Market cap of Natco Pharma Ltd is 16,344 Cr while Market cap of Pentokey Organy (India) Ltd is 26 Cr

What are the key factors driving the stock performance of Natco Pharma Ltd and Pentokey Organy (India) Ltd?

The stock performance of Natco Pharma Ltd and Pentokey Organy (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Natco Pharma Ltd and Pentokey Organy (India) Ltd?

As of June 15, 2025, the Natco Pharma Ltd stock price is INR ₹912.55. On the other hand, Pentokey Organy (India) Ltd stock price is INR ₹41.99.

How do dividend payouts of Natco Pharma Ltd and Pentokey Organy (India) Ltd compare?

To compare the dividend payouts of Natco Pharma Ltd and Pentokey Organy (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions